Screener
Recursion Pharmaceuticals, Inc. RXRX Restricted Cash Noncurrent
Restricted Cash Noncurrent at other companies
Other financials
Where this comes from
Reported directly by Recursion Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RestrictedCashNoncurrent.
The source filing: Recursion Pharmaceuticals, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 6:32 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001601830-26-000098
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Prepaid data assets | 8,680 | 11,742 |
| Other current assets | 29,321 | 28,566 |
| Total current assets | 603,462 | 812,845 |
| Restricted cash, non-current | 5,752 | 6,033 |
| Property and equipment, net | 89,623 | 103,931 |
| Operating lease right-of-use assets | 40,271 | 45,339 |
| Financing lease right-of-use assets | 17,179 | 20,210 |
| Intangible assets, net | 282,888 | 309,903 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Recursion Pharmaceuticals, Inc.'s restricted cash noncurrent?
- Recursion Pharmaceuticals, Inc. (RXRX) reported restricted cash noncurrent of $5.75M in Q2 2026.
- How has Recursion Pharmaceuticals, Inc.'s restricted cash noncurrent changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s restricted cash noncurrent increased by 2.2% year-over-year, from $5.63M to $5.75M.
- What is the long-term trend for Recursion Pharmaceuticals, Inc.'s restricted cash noncurrent?
- Over 5 years (2020 to 2025), Recursion Pharmaceuticals, Inc.'s restricted cash noncurrent has grown at a 14.7% compound annual growth rate (CAGR), from $3.04M to $6.03M.
- What does restricted cash noncurrent mean?
- Restricted Cash Noncurrent as reported by Recursion Pharmaceuticals, Inc. Class A Common Stock.
Ask your AI about Recursion Pharmaceuticals, Inc.'s restricted cash noncurrent.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude